異位性皮膚炎，注射杜避炎，有可能會另外衍生出面部及頸部紅疹

本篇研究，“Facial and neck erythema associated with dupilumab treatment: A systematic review”，請見這裡（外部網站），期刊摘要如下：

Background：

Neither dupilumab-associated facial erythema nor neck erythema was reported in phase 3 clinical trials for the treatment of atopic dermatitis, but there have been a number of reports of patients developing this adverse event in clinical practice.

Objective：

To outline all cases of reported dupilumab-associated facial or neck erythema to better characterize this adverse event, and identify potential etiologies and management strategies.

Methods：

A search was conducted on EMBASE and PubMed databases. Two independent reviewers identified relevant studies for inclusion and performed data extraction.

Results：

A total of 101 patients from 16 studies were reported to have dupilumab-associated facial or neck erythema.

A total of 52 of 101 patients (52%) had baseline atopic dermatitis facial or neck involvement and 45 of 101 (45%) reported different cutaneous symptoms from preexisting atopic dermatitis, possibly suggesting a different etiology.

Suggested etiologies included rosacea, allergic contact dermatitis, and head and neck dermatitis.

Most commonly used treatments included topical corticosteroids, topical calcineurin inhibitors, and antifungal agents.

In the 57 patients with data on the course of the adverse events, improvement was observed in 29, clearance in 4, no response in 16, and worsening in 8.

A total of 11 of 101 patients (11%) discontinued dupilumab owing to this adverse event.

Limitations：

Limited diagnostic testing, nonstandardized data collection and reporting across studies, and reliance on retrospective case reports and case series.

Conclusion：

Some patients receiving dupilumab develop facial or neck erythema that differs from their usual atopic dermatitis symptoms.

Prompt identification and empiric treatment may minimize distress and potential discontinuation of dupilumab owing to this adverse event.

原始論文

Facial and neck erythema associated with dupilumab treatment: A systematic review（外部網站）

Jo CE, Finstad A, Georgakopoulos JR, Piguet V, et al. Journal of the American Academy of Dermatology. 2021;84(5):1339-1347. doi:10.1016/j.jaad.2021.01.012

論文摘要（Google 翻譯）

以下為 Google 翻譯，並校正明顯錯誤，僅供參考，內容以英文原文為準。

與 dupilumab 治療相關的臉部與頸部紅斑：系統性回顧

背景：在治療異位性皮膚炎的第 3 期臨床試驗中，並未報告與 dupilumab 相關的臉部紅斑或頸部紅斑，但臨床實務中已有多份患者發生此不良事件的報告。

目的：整理所有已報告的 dupilumab 相關臉部或頸部紅斑病例，以更清楚描述此不良事件的特徵，並找出可能的病因與處置策略。

方法：檢索 EMBASE 與 PubMed 資料庫。由兩位獨立審查者篩選應納入的相關研究並擷取資料。

結果：16 項研究共報告 101 名患者出現 dupilumab 相關的臉部或頸部紅斑。

101 名患者中有 52 名（52%）在基線時已有臉部或頸部的異位性皮膚炎，101 名中有 45 名（45%）出現與原有異位性皮膚炎不同的皮膚症狀，可能意味著不同的病因。

推測的病因包括酒糟性皮膚炎、過敏性接觸性皮膚炎，以及頭頸部皮膚炎。

最常使用的治療包括外用類固醇、外用鈣調磷酸酶抑制劑與抗黴菌藥物。

在 57 名有不良事件病程資料的患者中，29 名改善、4 名完全消退、16 名無反應、8 名惡化。

101 名患者中共有 11 名（11%）因此不良事件停用 dupilumab。

限制：診斷檢查有限、各研究的資料收集與報告未標準化，且仰賴回溯性的病例報告與病例系列。

結論：部分接受 dupilumab 治療的患者會出現臉部或頸部紅斑，且與其平常的異位性皮膚炎症狀不同。

及早辨識並給予經驗性治療，可減少此不良事件造成的困擾及可能的 dupilumab 停藥。

小兒異位性皮膚炎，杜避炎施打後才衍生的臉部紅疹，中醫經方治療實例，請見這裡。

杜避炎治療後的中醫經方治療實例，請見這裡。

異位性皮膚炎，中醫經方的治療實例，請見這裡。

小兒異位性皮膚炎，中醫經方的治療實例，請見這裡。

成人異位性皮膚炎，中醫經方的治療實例，請見這裡。

異位性皮膚炎，期刊研究，請看這裡。

期刊研究整理，請見這裡。

更多杜避炎期刊，請見這裡。